13 Followers on Owler
GlobeImmune
is engaged in the development of therapeutic Tarmogen vaccines for the treatment of cancer and infectious diseases...
GlobeImmune
is engaged in the development of therapeutic Tarmogen vaccines for the treatment of cancer and infectious diseases...
1995
PublicIndependent CompanyOTCMKTSGBIM
News
Nov 26, 2018
BioPortfolio
GlobeImmune: Globeimmune Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13112018 Prices from USD $250
Aug 19, 2018
BioPortfolio
GlobeImmune: Globeimmune Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 17042018 Prices from USD $250
Mar 29, 2018
BioPortfolio
GlobeImmune: Globeimmune Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12032018 Prices from USD $250
Mar 20, 2018
BioPortfolio
GlobeImmune: Globeimmune Inc GBIM Financial and Strategic SWOT Analysis Review Report Updated 09032018 Prices from USD $300
Dec 01, 2017
BioPortfolio
GlobeImmune: Globeimmune Inc GBIM Financial and Strategic SWOT Analysis Review Report Updated 13112017 Prices from USD $300
Nov 21, 2017
BioPortfolio
GlobeImmune: Globeimmune Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 17102017 Prices from USD $250
Sep 25, 2017
BioPortfolio
GlobeImmune: Globeimmune Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 22082017 Prices from USD $250
Aug 30, 2017
techrockies
GlobeImmune: GlobeImmune Restarts Manufacturing
Aug 28, 2017
The Business Journals
GlobeImmune: Colorado biotech to restart operations at Louisville facility
Aug 28, 2017
BioSpace
GlobeImmune: GlobeImmune Provides Update On Recent Clinical Trial Developments
GlobeImmune Competitors
1
2
3
4
5
6
7
8
9
10
Looking for similar companies to GlobeImmune?
GlobeImmune Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$6.2M
GlobeImmune's revenue is the ranked 22th among it's top 10 competitors. The top 10 competitors average 2.8B. Over the last four quarters, GlobeImmune's revenue has grown by 35.5%. Specifically, in Q2 2015's revenue was $1.3M; in Q3 2015, it was $2.9M; in Q4 2015, it was $1M; in Q1 2016, GlobeImmune's revenue was $ < 1M.
GlobeImmune News
GlobeImmune Press Releases
GlobeImmune Headquarters
GlobeImmune Summary
ABOUT
Overview
GlobeImmune is engaged in the development of therapeutic Tarmogen vaccines for the treatment of cancer and infectious diseases. GlobeImmune was founded in 1995. GlobeImmune's headquarters is located in Louisville, Colorado, USA 80027. GlobeImmune's P...CEO
GlobeImmune's President, Jeffrey Dekker, currently has an approval rating of 69%. GlobeImmune's primary competitors are OncoMed Pharmaceuticals, Stemline, Verastem and 26 more.Website
globeimmune.comCompetitors
View 29 GlobeImmune competitors here.Acquisitions
There have been no acquisitions found related to GlobeImmuneInvestments
Recent investment data cannot be found related to GlobeImmuneFrequently Asked Questions about GlobeImmune
When was GlobeImmune founded?
GlobeImmune was founded in 1995Who is GlobeImmune's CEO?
GlobeImmune's CEO is Jeffrey DekkerHow much revenue does GlobeImmune generate?
GlobeImmune generates $6.2M in revenueHow much funding does GlobeImmune have?
GlobeImmune has historically raised $96.2M in funding
Where is GlobeImmune's headquarters?
GlobeImmune's headquarters is in Louisville Colorado, USAHow many employees does GlobeImmune have?
GlobeImmune has 22 employeesWhat sector does GlobeImmune operate in?
GlobeImmune is in Pharmaceuticals, BiotechnologyWho are GlobeImmune's competitors?
GlobeImmune's top competitors are OncoMed Pharmaceuticals, Stemline, Verastem